Keybank National Association OH Boosts Holdings in DexCom, Inc. (NASDAQ:DXCM)

Keybank National Association OH grew its holdings in shares of DexCom, Inc. (NASDAQ:DXCMGet Rating) by 469.7% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,056 shares of the medical device company’s stock after acquiring an additional 3,344 shares during the quarter. Keybank National Association OH’s holdings in DexCom were worth $302,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the business. Baillie Gifford & Co. increased its stake in shares of DexCom by 297.4% in the second quarter. Baillie Gifford & Co. now owns 18,099,399 shares of the medical device company’s stock worth $1,348,948,000 after buying an additional 13,545,106 shares during the period. Banque Pictet & Cie SA boosted its holdings in shares of DexCom by 171.4% during the 2nd quarter. Banque Pictet & Cie SA now owns 103,933 shares of the medical device company’s stock valued at $7,746,000 after buying an additional 65,639 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its stake in DexCom by 284.7% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 438,560 shares of the medical device company’s stock worth $32,686,000 after purchasing an additional 324,557 shares in the last quarter. Ascent Group LLC boosted its stake in DexCom by 333.7% in the 2nd quarter. Ascent Group LLC now owns 4,680 shares of the medical device company’s stock worth $384,000 after purchasing an additional 3,601 shares in the last quarter. Finally, Reynders McVeigh Capital Management LLC boosted its stake in DexCom by 298.8% in the 2nd quarter. Reynders McVeigh Capital Management LLC now owns 26,388 shares of the medical device company’s stock worth $1,967,000 after purchasing an additional 19,771 shares in the last quarter. 92.34% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Wells Fargo & Company boosted their target price on DexCom from $102.00 to $128.00 and gave the stock an “overweight” rating in a research report on Friday, October 28th. Jefferies Financial Group initiated coverage on shares of DexCom in a report on Wednesday, October 12th. They issued a “buy” rating and a $125.00 target price for the company. Cowen increased their target price on shares of DexCom from $85.00 to $114.00 in a report on Friday, October 28th. BTIG Research lifted their price objective on shares of DexCom to $126.00 in a research report on Tuesday, November 1st. Finally, Raymond James upped their target price on shares of DexCom from $101.00 to $125.00 and gave the stock an “outperform” rating in a research report on Friday, October 28th. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $120.24.

Insider Transactions at DexCom

In other news, Director Steven Robert Pacelli sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, August 23rd. The shares were sold at an average price of $84.21, for a total value of $84,210.00. Following the completion of the sale, the director now owns 137,700 shares in the company, valued at approximately $11,595,717. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.41% of the company’s stock.

DexCom Price Performance

DexCom stock opened at $115.96 on Friday. The firm has a 50-day moving average price of $97.04 and a 200-day moving average price of $86.94. The firm has a market capitalization of $44.79 billion, a PE ratio of 213.76, a price-to-earnings-growth ratio of 4.31 and a beta of 1.21. The company has a current ratio of 3.77, a quick ratio of 3.43 and a debt-to-equity ratio of 1.08. DexCom, Inc. has a 12-month low of $66.89 and a 12-month high of $164.86.

DexCom Profile

(Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

Featured Stories

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.